Get the Stockscreener App
34.10
0.41%
0.14
After Hours:
34.47
0.37
+1.09%
Amylyx Pharmaceuticals Inc stock is traded at $34.10, with a volume of 885.09K.
It is up +0.41% in the last 24 hours and up +55.92% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
See More
Previous Close:
$33.96
Open:
$33.38
24h Volume:
885.09K
Relative Volume:
0.37
Market Cap:
$3.80B
Revenue:
$-665.00K
Net Income/Loss:
$-150.11M
P/E Ratio:
-22.63
EPS:
-1.5071
Net Cash Flow:
$-124.53M
1W Performance:
-1.84%
1M Performance:
+55.92%
6M Performance:
+126.58%
1Y Performance:
+242.71%
1-Day Range:
$33.38
$34.24
1-Week Range:
$32.98
$35.48
52-Week Range:
$9.75
$41.14
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Phone
617-682-0917
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
34.10 | 4.42B | -665.00K | -150.11M | -124.53M | -1.5071 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-26 | Initiated | Stifel | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
The Manufacturers Life Insurance Company Makes New $679,000 Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Amylyx Pharmaceuticals (AMLX) director exercises 50K stock options - Stock Titan
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? - Yahoo Finance
Amylyx Pharmaceuticals (AMLX) Is Down 10.1% After Strong Phase 3 Avexitide Data And $500M Equity Raise – Has The Bull Case Changed? - webull.com
Oracle Stock Stands Out Among Healthy High Growth Potential Picks - Sahm
Oracle Stock And Palantir Shares Stand Out For High Growth Investors - Sahm
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Guggenheim raises Amylyx stock price target on financing, trial data By Investing.com - Investing.com Australia
Guggenheim raises Amylyx stock price target on financing, trial data - Investing.com
Broadcom Stock Leads 3 AI Infrastructure Picks With Strong Growth Potential - Sahm
Rocket Lab Stock Leads 3 High Growth Picks With Fresh Earnings Upside - Sahm
LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week - Yahoo Finance
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company? - Yahoo Finance
MercadoLibre Stock And 2 High Growth Picks With Strong Balance Sheets - Sahm
Amylyx Pharmaceuticals (AMLX) co-CEO nets 60K performance shares - Stock Titan
Amylyx (NASDAQ: AMLX) CMO’s stock award lifts stake to 288,092 shares - Stock Titan
Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide - TipRanks
Amylyx Pharmaceuticals Announces $471.7 Million Public Stock Offering Priced at $35.50 Per Share - Kalkine Media
Amylyx Pharmaceuticals Prices 14.09M-Share Public Offering at $35.50; Nets ~$472M - TradingView
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock - BioSpace
Amylyx Pharmaceuticals Jumps to Fresh Three-Year High as Avexitide Phase 3 Results Bolster Commercial Path - Vinanet
HC Wainwright Has Strong Forecast for AMLX FY2028 Earnings - MarketBeat
39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by GSA Capital Partners LLP - MarketBeat
Amylyx Pharmaceuticals (AMLX) CEO granted 60K shares - Stock Titan
Amylyx prices $500M stock offering at $35.50 per share - Investing.com
Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock - TradingView
Guggenheim raises Amylyx stock price target on trial results By Investing.com - Investing.com Australia
Amylyx (AMLX) Q2 2026 Earnings Call Transcript - AOL.com
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win - The Globe and Mail
AMYLYX PHARMACEUTICALS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $40 FROM $28 - Bitget
Amylyx successful phase 3 trials for blood sugar drug - EMJ
AMYLYX PHARMACEUTICALS, INC. : MIZUHO RAISES TARGET PRICE TO $42 FROM $30 - Bitget
Amgen cans its TScan partnership; Amylyx reveals $350M offering - Endpoints News
Amylyx Pharmaceuticals (NASDAQ:AMLX) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $55 - Moomoo
Guggenheim Boosts Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $55.00 - MarketBeat
A Quick Look at Today's Ratings for Amylyx Pharmaceuticals(AMLX.US), With a Forecast Between $32 to $55 - Moomoo
Guggenheim raises Amylyx stock price target on trial results - Investing.com
Amylyx Stock Sinks As Big Share Sale Spooks Wall Street - TipRanks
Robert W. Baird Forecasts Strong Price Appreciation for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
Amylyx’s $35m-acquired PBH drug meets endpoints in Phase III trial - Yahoo
Mizuho Adjusts PT on Amylyx Pharmaceuticals to $42 From $30, Maintains Outperform Rating - Moomoo
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at Wolfe Research - MarketBeat
Amylyx Pharmaceuticals (AMLX) Posts Phase 3 Avexitide Win And Follows With Equity Raise - Yahoo Finance
Jason Gerberry Boosts Amylyx Price Target to $39 on Strong LUCIDITY Phase 3 Avexitide Data and $1.8B Peak Sales Outlook - TipRanks
Why Flexsteel Industries Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket - Sahm
Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level - sahmcapital.com
Amylyx drug cuts low blood sugar episodes in bariatric surgery patients in key trial - KWSN
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amylyx Pharmaceuticals Inc Stock (AMLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mazzariello Gina | Chief Legal Officer |
Jul 09 '26 |
Sale |
18.32 |
15,000 |
274,746 |
194,090 |
| Mazzariello Gina | Chief Legal Officer |
Jul 10 '26 |
Sale |
17.61 |
15,000 |
264,122 |
179,090 |
1.66%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):